vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and SailPoint, Inc. (SAIL). Click either name above to swap in a different company.
SailPoint, Inc. is the larger business by last-quarter revenue ($281.9M vs $183.1M, roughly 1.5× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -12.8%, a 26.1% gap on every dollar of revenue. On growth, SailPoint, Inc. posted the faster year-over-year revenue change (6.7% vs -1.8%). SailPoint, Inc. produced more free cash flow last quarter ($52.5M vs $24.6M).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Steel Authority of India Limited (SAIL) is an Indian public sector steel manufacturing corporation based in New Delhi designated as Maharatna CPSE. It is the largest government-owned steel producer, with an annual production of 18.29 million metric tons. Incorporated on 24 January 1973, SAIL has 51,351 employees and is under the administrative control of the Ministry of Steel.
AMPH vs SAIL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $281.9M |
| Net Profit | $24.4M | $-36.0M |
| Gross Margin | 46.8% | 66.3% |
| Operating Margin | 19.4% | -14.8% |
| Net Margin | 13.3% | -12.8% |
| Revenue YoY | -1.8% | 6.7% |
| Net Profit YoY | -35.7% | -240.9% |
| EPS (diluted) | $0.51 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $281.9M | ||
| Q3 25 | $191.8M | $264.4M | ||
| Q2 25 | $174.4M | $230.5M | ||
| Q1 25 | $170.5M | $240.1M | ||
| Q4 24 | $186.5M | — | ||
| Q3 24 | $191.2M | $198.6M | ||
| Q2 24 | $182.4M | $187.7M | ||
| Q1 24 | $171.8M | — |
| Q4 25 | $24.4M | $-36.0M | ||
| Q3 25 | $17.4M | $-10.6M | ||
| Q2 25 | $31.0M | $-187.3M | ||
| Q1 25 | $25.3M | $-80.1M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $-87.1M | ||
| Q2 24 | $37.9M | $-89.2M | ||
| Q1 24 | $43.2M | — |
| Q4 25 | 46.8% | 66.3% | ||
| Q3 25 | 51.4% | 67.3% | ||
| Q2 25 | 49.6% | 55.4% | ||
| Q1 25 | 50.0% | 66.5% | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | 62.1% | ||
| Q2 24 | 52.2% | 61.5% | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | -14.8% | ||
| Q3 25 | 13.2% | -15.4% | ||
| Q2 25 | 24.2% | -80.3% | ||
| Q1 25 | 21.9% | -12.6% | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 29.8% | -33.2% | ||
| Q2 24 | 30.3% | -36.3% | ||
| Q1 24 | 27.9% | — |
| Q4 25 | 13.3% | -12.8% | ||
| Q3 25 | 9.0% | -4.0% | ||
| Q2 25 | 17.8% | -81.3% | ||
| Q1 25 | 14.8% | -33.4% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | -43.9% | ||
| Q2 24 | 20.8% | -47.5% | ||
| Q1 24 | 25.1% | — |
| Q4 25 | $0.51 | $-0.06 | ||
| Q3 25 | $0.37 | $-0.02 | ||
| Q2 25 | $0.64 | $-0.42 | ||
| Q1 25 | $0.51 | $-6.50 | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | $-2.97 | ||
| Q2 24 | $0.73 | $-0.77 | ||
| Q1 24 | $0.81 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $298.1M |
| Total DebtLower is stronger | $608.7M | $0 |
| Stockholders' EquityBook value | $788.8M | $6.8B |
| Total Assets | $1.6B | $7.5B |
| Debt / EquityLower = less leverage | 0.77× | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $298.1M | ||
| Q3 25 | $276.2M | $271.1M | ||
| Q2 25 | $231.8M | $228.1M | ||
| Q1 25 | $236.9M | $121.3M | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | $89.7M | ||
| Q2 24 | $217.8M | $146.8M | ||
| Q1 24 | $289.6M | — |
| Q4 25 | $608.7M | $0 | ||
| Q3 25 | $608.6M | $0 | ||
| Q2 25 | $607.7M | $0 | ||
| Q1 25 | $603.9M | $1.0B | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $6.8B | ||
| Q3 25 | $776.7M | $6.8B | ||
| Q2 25 | $757.5M | $6.8B | ||
| Q1 25 | $751.3M | $-5.6B | ||
| Q4 24 | $732.3M | — | ||
| Q3 24 | $727.7M | $-701.3M | ||
| Q2 24 | $713.3M | $-622.5M | ||
| Q1 24 | $672.4M | — |
| Q4 25 | $1.6B | $7.5B | ||
| Q3 25 | $1.7B | $7.4B | ||
| Q2 25 | $1.6B | $7.4B | ||
| Q1 25 | $1.6B | $7.4B | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.6B | — |
| Q4 25 | 0.77× | 0.00× | ||
| Q3 25 | 0.78× | 0.00× | ||
| Q2 25 | 0.80× | 0.00× | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $53.6M |
| Free Cash FlowOCF − Capex | $24.6M | $52.5M |
| FCF MarginFCF / Revenue | 13.4% | 18.6% |
| Capex IntensityCapex / Revenue | 4.5% | 0.4% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $53.6M | ||
| Q3 25 | $52.6M | $49.9M | ||
| Q2 25 | $35.6M | $-96.8M | ||
| Q1 25 | $35.1M | — | ||
| Q4 24 | $29.0M | — | ||
| Q3 24 | $60.0M | — | ||
| Q2 24 | $69.1M | $-55.4M | ||
| Q1 24 | $55.3M | — |
| Q4 25 | $24.6M | $52.5M | ||
| Q3 25 | $47.2M | $49.0M | ||
| Q2 25 | $25.0M | $-99.0M | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $63.1M | $-56.0M | ||
| Q1 24 | $46.5M | — |
| Q4 25 | 13.4% | 18.6% | ||
| Q3 25 | 24.6% | 18.5% | ||
| Q2 25 | 14.3% | -43.0% | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 34.6% | -29.8% | ||
| Q1 24 | 27.1% | — |
| Q4 25 | 4.5% | 0.4% | ||
| Q3 25 | 2.8% | 0.4% | ||
| Q2 25 | 6.1% | 1.0% | ||
| Q1 25 | 6.3% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 3.3% | 0.3% | ||
| Q1 24 | 5.1% | — |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
SAIL
| Software As A Service Saa S | $156.0M | 55% |
| Term Subscriptions Services | $65.1M | 23% |
| Maintenance | $38.0M | 13% |
| Other | $15.7M | 6% |
| Other Subscription Services | $7.1M | 3% |
